Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| RADX | Radiopharm Theranostics | $10.83 | $6.57 | 154.24% | 35.5M | $40M | $3.50$16.25 |
| ARTV | Artiva Biotherapeutics | $6.42 | $3.12 | 94.55% | 44M | $81M | $1.47$11.55 |
| KXIN | Kaixin | $4.69 | $1.37 | 41.27% | 2.1M | $20M | $2.94$75.00 |
| ASTI | Ascent Solar Technologies | $4.30 | $1.18 | 37.74% | 5M | $11M | $1.10$4.60 |
| CPIX | Cumberland Pharmaceuticals | $3.13 | $0.60 | 23.86% | 628.5K | $38M | $1.85$7.25 |
| KYTX | Kyverna Therapeutics | $10.85 | $2.07 | 23.58% | 18.1M | $385M | $1.78$13.67 |
| FGEN | FibroGen | $10.28 | $1.90 | 22.65% | 319.3K | $34M | $4.85$21.94 |
| RKLZ | Tidal Trust II - Defiance Daily Target 2x Short Rklb ETF | $10.01 | $1.61 | 19.18% | 1.1M | - | $7.50$25.51 |
| QBTZ | Tidal Trust II - Defiance Daily Target 2x Short Qbts ETF | $15.35 | $2.46 | 19.09% | 2.3M | - | $8.77$32.28 |
| IONZ | Tidal Trust II - Defiance Daily Target 2x Short Ionq ETF | $25.29 | $3.97 | 18.62% | 1.2M | - | $12.48$137.71 |
Related Articles
Featured Article
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
Leo Miller|Aug 29, 2024
Artiva's revolutionary cell therapies could be a patient lifeline and a goldmine for investors.
Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?
Alex Carchidi|Feb 25, 2024
The market's excited for these stocks, but there's no rush to buy them.
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock?
Alex Carchidi|Jul 1, 2023
Its pipeline is looking thin, and it might hit another speed bump quite soon.
Advertisement
Is It Too Late to Buy Rent the Runway Stock?
Leo Sun|Dec 10, 2022
The apparel rental marketplace could be on the cusp of a comeback.
Buying This IPO Could Be a Big Mistake
Asit Sharma, CPA|Nov 9, 2021
Rent the Runway is looking to invent a cloud-based wardrobe for fashionistas across the world, but its business is already looking shabby.
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
Keith Speights|Jul 29, 2021
FDA approval of roxadustat seems unlikely.
FibroGen's Anemia Drug Goes to FDA for Review
Eric Volkman|Feb 12, 2020
A decision on Roxadustat should arrive by Dec. 20.
FibroGen Appoints Enrique Conterno as Its New CEO
Brian Orelli, PhD|Jan 6, 2020
The former Eli Lilly executive will be tasked with launching the biotech's anemia drug roxadustat.
![Enrique-Conterno[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F552569%2Fenrique-conterno1.jpg&w=384&op=resize)
Here’s Why FibroGen’s Stock Popped Friday
David Haen|Nov 11, 2019
FibroGen reported highly anticipated clinical data on Friday for its lead drug roxadustat in chronic kidney disease.
4 Biotech Stocks With Major Catalysts in April
Cory Renauer|Apr 2, 2019
April's about to shower biopharma investors with important updates that could move these stocks.
